Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada.
Am J Physiol Heart Circ Physiol. 2010 May;298(5):H1382-90. doi: 10.1152/ajpheart.00424.2009. Epub 2010 Feb 26.
Stimulation of cardiac AMP-activated protein kinase (AMPK) has been demonstrated in both prohypertrophic and antihypertrophic settings, although the reasons for such discrepant results are not well understood. We determined how AMPK is regulated in response to phenylephrine-induced cardiomyocyte hypertrophy and assessed whether AMPK activity may be a factor underlying the antihypertrophic effect of adenosine receptor agonists. The role of AMPK in hypertrophic responses was determined by assessing the effect of the AMPK activator 5-aminoimidazole-4-carboxyamide ribonucleoside on three hypertrophic indexes, including protein synthesis, cell surface area, and fetal gene expression. The changes in phosphorylation of the catalytic alpha-subunit of AMPK at two different sites, Thr(172) and Ser(485/491), in response to phenylephrine and adenosine receptor agonists were also examined. 5-Aminoimidazole-4-carboxyamide ribonucleoside completely abolished phenylephrine-induced increases in protein synthesis, cell surface area, and fetal gene expression. AMPK phosphorylation time course studies revealed that phenylephrine induced a time-dependent activation at site Ser(485/491), in contrast to adenosine receptor agonists, which demonstrated rapid AMPK phosphorylation at Thr(172). Furthermore, the phosphorylation at Ser(485/491) by phenylephrine was not affected by the addition of adenosine receptor agonists, although, conversely, phosphorylation of AMPK at Thr(172) by adenosine receptor agonists was abrogated by the addition of phenylephrine. We propose from these results that cardiomyocyte hypertrophic and antihypertrophic responses, at least with respect to inhibition of phenylephrine-induced hypertrophy by adenosine receptor agonists, are mediated by multisite AMPK regulation. The latter are reflected by increased phosphorylation at Ser(485/491) and at Thr(172), associated with prohypertrophic and antihypertrophic responses, respectively.
刺激心脏 AMP 激活的蛋白激酶(AMPK)已在促肥厚和抗肥厚环境中得到证实,尽管导致这种不一致结果的原因尚不清楚。我们确定了 AMPK 如何响应苯肾上腺素诱导的心肌细胞肥大而被调节,并评估了 AMPK 活性是否可能是腺苷受体激动剂抗肥厚作用的基础。通过评估 AMPK 激活剂 5-氨基咪唑-4-甲酰胺核苷对三种肥大指标(包括蛋白质合成、细胞表面积和胎儿基因表达)的影响,确定了 AMPK 在肥大反应中的作用。还检查了 AMPK 催化α亚基在两个不同位点(Thr(172)和 Ser(485/491))对苯肾上腺素和腺苷受体激动剂的磷酸化变化。5-氨基咪唑-4-甲酰胺核苷完全消除了苯肾上腺素诱导的蛋白质合成、细胞表面积和胎儿基因表达的增加。AMPK 磷酸化时程研究表明,苯肾上腺素诱导 Ser(485/491)位点的时间依赖性激活,而与腺苷受体激动剂相反,腺苷受体激动剂快速磷酸化 Thr(172)位点。此外,苯肾上腺素引起的 Ser(485/491)磷酸化不受腺苷受体激动剂的影响,尽管相反,腺苷受体激动剂引起的 Thr(172)位点的 AMPK 磷酸化被苯肾上腺素所阻断。从这些结果中,我们提出心肌细胞肥大和抗肥大反应(至少与腺苷受体激动剂抑制苯肾上腺素诱导的肥大有关)是通过多部位 AMPK 调节介导的。后者反映为 Ser(485/491)和 Thr(172)的磷酸化增加,分别与促肥大和抗肥大反应相关。